Pharmaceutical company H. Lundbeck A/S (CPH:HLUN) announced on Thursday the initiation of a clinical trial for its CD40L blocker, Lu AG22515, targeting Thyroid Eye Disease, an autoimmune condition that can cause debilitating and disfiguring effects.

This proof-of-concept trial aims to assess the efficacy, safety and tolerability of Lu AG22515 in patients with moderate-to-severe manifestations of the disease. The 20453A trial will be interventional, open-label and involve a single group of 19 adult participants. By inhibiting CD40L, Lu AG22515 seeks to modulate both B and T cell activation, presenting a promising strategy for addressing autoimmune-related central nervous system disorders.

Developed under a licensing and collaboration agreement with AprilBio Co., LTD, Lu AG22515 leverages innovative anti-Serum Albumin Fab Associated technology for high potency and minimized side effects. This trial underscores Lundbeck's commitment to advancing treatments for severe and rare conditions, positioning Lu AG22515 as a potential novel therapeutic option. Thyroid Eye Disease results from autoantibody activation of orbital fibroblasts, leading to inflammation and tissue expansion around the eyes. Advancements in this area could significantly impact patient outcomes in neuroimmunology.